Skip to main content
. 2024 Apr 29;13(4):596–609. doi: 10.21037/tp-24-66

Table 1. The clinical characteristics of the four patients with IFS analyzed in this study.

Patient ID Gender Age at onset Clinical manifestations Local lesion Other lesions Surgery Histopathological characteristics ETV6-NTRK3 gene fusion IRS staging Follow-up
Site Diameter at diagnosis (cm) Diagnosis IHC
Patient 1 M After birth Vomit Abdominal and pelvic cavity 8.80 No Biopsy IFS Vimentin (+), Ki-67 30% (+),
alpha-SMA (−), CD34 (−),
S-100 (−), Desmin (−)
Yes III Dead
Patient 2 M 2 months old Painless lump From the pelvic area to the right buttock 1.30 No Biopsy IFS Vimentin (+), Ki-67 40% (+),
alpha-SMA (+), CD34 (−),
S-100 (−), Desmin (−)
Yes III Survival
Patient 3 F After birth Right eye protrusion Behind the right eyeball 3.50 No Resection IFS Vimentin (+), Ki-67 20% (+),
alpha-SMA (−), CD34 (−),
S-100 (−), Desmin (−)
Yes II Survival
Patient 4 M After birth Vomit and bilateral lower limb swelling From the pelvic area to the right buttock 6.00 No Biopsy IFS Vimentin (+), Ki-67 15% (+),
alpha-SMA (+), CD34 (−),
S-100 (+), Desmin (−)
Yes III Survival

IFS, infantile fibrosarcoma; M, male; F, female; cm, centimeter; IHC, immunohistochemistry; SMA, smooth muscle action; IRS, intergroup rhabdomyosarcoma study.